Janssen Presented Longer-Term Data for TECVAYLI Showing a Duration Response of 22 Months In Patients With Relapsed Or Refractory Multiple Myeloma
Portfolio Pulse from Charles Gross
Janssen, a subsidiary of Johnson & Johnson, announced long-term data from the Phase 1/2 MajesTEC-1 study, showing sustained efficacy and safety of TECVAYLI in treating patients with relapsed or refractory multiple myeloma. Nearly half of the patients achieved a complete response or better.
June 05, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's subsidiary Janssen announced positive long-term data for TECVAYLI in treating relapsed or refractory multiple myeloma, with nearly half of patients achieving a complete response.
The positive long-term data from the MajesTEC-1 study demonstrates the sustained efficacy and safety of TECVAYLI in treating relapsed or refractory multiple myeloma. This is likely to have a positive impact on Johnson & Johnson's stock price in the short term, as it indicates the potential for increased revenue from the drug and strengthens the company's position in the oncology market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100